American Well vs OptimizeRx
AMWL and OPRX side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMWL and OPRX compare
American Well is the larger company, worth 1.5 times as much as OptimizeRx ($193M against $125M).
OptimizeRx grew revenue faster over the last twelve months (−5.8% versus −19.0% for American Well).
OptimizeRx keeps more of each dollar of sales as profit, with a net margin of 4.7% compared with −35.7% at American Well.
American Well scores higher on the StockData Score (11 against 10 for OptimizeRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMWL | OPRX |
|---|---|---|
| Size and price | ||
| Market cap | $193M | $125M |
| Share price | $11.34 | $6.64 |
| Change, 1 year | 184% | −57.1% |
| Change, 5 years | −91.5% | −90.3% |
| Beta (5Y) | 1.84 | 1.56 |
| Employees | 562 | 104 |
| StockData Score | ||
| Total score | 11 (better) | 10 |
| Valuation score | 3 | 3 |
| Growth score | 2 | 2 |
| Performance score | 1 | 2 (better) |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 27.7× |
| P/S | 0.9× (better) | 1.3× |
| P/B | 0.9× (better) | 1.0× |
| EV/EBITDA | – | 7.9× |
| P/FCF | – | 6.8× |
| FCF yield | −13.7% | 14.7% (better) |
| Fair value | $18.90 | $10.13 |
| Margin of safety | 40.0% (better) | 34.5% |
| Growth | ||
| Revenue growth (TTM) | −19.0% | −5.8% (better) |
| Revenue growth, 5Y average | 0.33% | 20.4% (better) |
| Profitability | ||
| Gross margin | 51.9% | 73.2% (better) |
| Operating margin | −37.3% | 11.1% (better) |
| Net margin | −35.7% | 4.7% (better) |
| FCF margin | −12.1% | 18.6% (better) |
| Return on equity | −31.0% | 3.7% (better) |
| Return on invested capital | −145% | 5.8% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.15 (better) |
| Net debt / EBITDA | – | −0.33 |
| Interest coverage | – | 2.3× |
| Current ratio | 2.90 | 5.58 (better) |
| Altman Z-score | −7.18 | 2.72 (better) |
| Piotroski F-score | 6 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 42.3% | 59.6% |
| Held by insiders | 15.8% | 19.4% |
| Insider net buying, 12 months | −$1.0M | −$18.8K (better) |
| Short interest, % of float | 1.7% | 7.8% |
Go deeper
- AMWL stock overview
- AMWL income statement
- AMWL valuation and score
- OPRX stock overview
- OPRX income statement
- OPRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.